Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tunable Nanoparticle Thin-Film Reveals Distance Dependence of Auger-Mediated Radiation Enhancement in Diffuse Midline Glioma.

ACS nano·2026
Same author

Synovial metaplasia in capsules of macrotextured and smooth breast implants: A comparative study.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026
Same author

Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.

bioRxiv : the preprint server for biology·2026
Same author

Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.

Gels (Basel, Switzerland)·2026
Same author

Cell-based cytokine patch for localized immunomodulation and accelerated healing in rodent and porcine wounds.

Nature biomedical engineering·2026
Same author

Peptoid-Based Nanosheets Exhibiting Broad Antiviral Activity against Enveloped RNA Viruses.

ACS nano·2026

Related Experiment Video

Updated: Jun 6, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A pretargeted nanoparticle system for tumor cell labeling.

Jonathan Gunn1, Steven I Park, Omid Veiseh

  • 1Department of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.

Molecular Biosystems
|November 26, 2010
PubMed
Summary

This study introduces a novel nanoparticle system for cancer diagnostics and therapeutics. A fusion protein (FP) prelabels target cells, allowing a single nanoparticle formulation to bind various cancer types, enhancing diagnostic and therapeutic strategies.

More Related Videos

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
08:26

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles

Published on: October 19, 2015

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
08:26

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles

Published on: October 19, 2015

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Targeted delivery of nanoparticles in cancer diagnostics and therapeutics requires specific ligands for neoplastic cells, often necessitating multiple systems for different diseases.
  • Current strategies face limitations due to the need for disease-specific targeting ligands on nanoparticles.

Purpose of the Study:

  • To develop a versatile nanoparticle system for cancer diagnostics and therapeutics that overcomes the limitations of single-target specificity.
  • To present a novel targeting pretreatment strategy using a fusion protein (FP) and a secondary biotinylated nanoparticle label.

Main Methods:

  • A fusion protein (FP) was used to selectively prelabel target cellular epitopes.
  • Biotinylated iron oxide nanoparticles were employed as secondary labels that bind to the FP on target cells.
  • The approach was validated using two fusion proteins against lymphoma (Ramos) and leukemia (Jurkat) cell lines.

Main Results:

  • The single nanoparticle formulation, when used with different fusion proteins, demonstrated the ability to bind to a variety of target cells.
  • Positive labeling rates of 72.2% for lymphoma (Ramos) and 91.1% for leukemia (Jurkat) were achieved.
  • Transmission electron microscopy (TEM) revealed nanoparticle endocytosis via attachment to the non-internalizing CD20 epitope.

Conclusions:

  • The presented nanoparticle system, combined with a fusion protein pretreatment strategy, offers a versatile platform for cancer diagnostics and therapeutics.
  • This approach enables the use of a single nanoparticle formulation for multiple cancer types, simplifying treatment strategies.
  • The findings highlight the potential of this method to enhance the efficacy and applicability of nanoparticle-based cancer interventions.